がん研究のアーカイブ

  • ISSN: 2254-6081
  • ジャーナル h-index: 13
  • 雑誌引用スコア: 3.58
  • ジャーナルのインパクトファクター: 3.12
インデックス付き
  • 中国国家知識基盤 (CNKI)
  • サイテファクター
  • OCLC-WorldCat
  • パブロン
  • ジュネーブ医学教育研究財団
  • Google スカラー
  • 秘密検索エンジン研究所
このページをシェアする

抽象的な

Toll-like Receptor: Breast Cancer Development and Immunotherapy

Emili Manna

Breast cancer is well known leading causes of mortality in the females. Current studies have suggested that the imbalances in inflammatory and immune-associated proteins may also give rise to breast cancer and disease progression. Toll like receptors (TLRs) are essential components of innate immune system that protect the host against bacterial and viral infection. It not only express in innate immune cell, its expression also found in breast cancer cells. Activation of TLRs leads to the activation of inflammatory pathways. Recent reports provide such evidences, which suggest the important role of TLRs in breast cancer pathogenesis and recurrence. TLRs are not only involved in cancer development, but also involve in anticancer immunotherapy. There are some agonists and antagonist of TLRs, used in anticancer immunotherapy, is targeted in clinic successfully.

 

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません